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Abstract: In global cancer statistics, colorectal carcinoma (CRC) ranks third by incidence and second
by mortality, causing 10.0% of new cancer cases and 9.4% of oncological deaths worldwide. Despite
the development of screening programs and preventive measures, there are still high numbers of
advanced cases. Multiple problems compromise the treatment of metastatic colorectal cancer, one of
these being cancer stem cells—a minor fraction of pluripotent, self-renewing malignant cells capable
of maintaining steady, low proliferation and exhibiting an intriguing arsenal of treatment resistance
mechanisms. Currently, there is an increasing body of evidence for intricate associations between
inflammation, epithelial–mesenchymal transition and cancer stem cells. In this review, we focus on
inflammation and its role in CRC stemness development through epithelial–mesenchymal transition.
Keywords: colorectal cancer; stem cells; inflammation; epithelial–mesenchymal transition; immuno-
histochemistry
1. Introduction
Colorectal cancer (Figure 1) has already been targeted by multiple scientific studies,
and it remains a hot research topic in oncology. Nevertheless, colorectal carcinoma (CRC)
still represents one of deadliest tumours worldwide. According to global cancer statistics
(GLOBOCAN estimates), 19.3 million new cancer cases were diagnosed in 2020. CRC
represented 10.0% of cancer incidence and caused 9.4% of tumour-induced deaths, ranking
third by incidence (after breast cancer, 11.7% and lung cancer, 11.4%) and second among
oncological causes of mortality, surpassed only by lung cancer, which was responsible
for 18.0% of cancer-induced deaths [1]. Due to the development of diagnostic tools and
population screening programs, including colonoscopy, the overall mortality has reduced,
in some case-control and prospective cohort studies, by as much as 65–88% [2]. One of
the main causes for CRC development is the transformation of a normal colon epithelium
into adenomas via multiple genetic and epigenetic aberrations [3]. Removal of adenomas,
as a result of a wide screening program, has shown great results in the USA, where the
incidence of colorectal carcinoma in people aged 50 years or older declined by 32% (2000–
2013) and mortality by 34% (2000–2014) [4]. However, surveillance after adenoma removal
is necessary, since CRC incidence in patients with high-risk features of adenomas (Table 1)
is at least two times higher than in patients having low and intermediate risk [5]. The
current treatment of CRC is mainly based on local surgical intervention, radiation and
systemic chemotherapy [6–8]. Nevertheless, there are still high numbers of advanced
cases, affected by distant metastasis and thus having a worse 5-year survival rate of
10.5% [9]. Multiple problems compromise the treatment of metastatic colorectal cancer, one
of these being cancer stem cells (CSCs)—a minor fraction of malignant cells maintaining
steady, low proliferation and exhibiting an intriguing arsenal of treatment resistance
mechanisms [10,11].
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Figure 1. Aggressive features of colorectal carcinoma. (A)—Gross view of large, ulcerated colorectal carcinoma. (B)—
Colorectal adenocarcinoma exhibiting marked perineural growth. Visualisation by haematoxylin and eosin (HE), original 
magnification (OM) 100×. (C)—High proliferation activity by Ki-67. Immunoperoxidase, OM 200×. (D)—Metastatic colo-
rectal adenocarcinoma in a lymph node. HE, OM 100×. 
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(B)—Colorectal adenocarcinoma exhibiting marked perineural growth. Visualisation by haematoxylin and eosin (HE), orig-
inal magnification (OM) 100×. (C)—High proliferation activity by Ki-67. Immunoperoxidase, OM 200×. (D)—Metastatic
colorectal adenocarcinoma in a lymph node. HE, OM 100×.
Table 1. Risk features for colorectal cancer development after adenoma removal.
High risk
• 5 or more adenomas <10 mm;
• 3 or more adenomas with at least 1 ≥ 10 mm;
• Incomplete colonoscopy/colonoscopy of unknown completeness;
• High-grade dysplasia;
• Proximal polyps;
• Adenomas ≥20 mm;
Intermediate risk
• 3–4 adenomas <10 mm;
• 1–2 adenomas with at least 1 ≥ 10 mm;
Low risk
• 1–2 adenomas <10 mm
Regarding the origin of CSCs, there are currently two main theories: (1) oncogenic
mutations accumulating within normal adult cells or embryonic stem cells, leading to
uncontrolled proliferation [12] or (2) dedifferentiation into a stem-like state, which in
a cancer cell would produce CSC [13]. Although CSC-targeting treatments are under
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development, CSCs exhibit heterogeneity that leads to cancer subtype switching, further
affecting treatment and prognosis [14].
Inflammation has a well-known role in tumour pathogenesis. Regarding colorectal
carcinoma, long-standing inflammatory bowel disease, including both Crohn’s disease
and ulcerative colitis, is associated with a 1.4- to 2.2-fold increased risk of colorectal car-
cinoma [15]. In an already established tumour, the intensity or cellular composition of
inflammation can have prognostic importance, and inflammation is also involved in gener-
ation of pre-metastatic niches [16,17]. Hence, in colorectal carcinogenesis, inflammation is
pathogenetically significant over the whole course of tumour development, from initiation
and throughout progression. Relationships between inflammation and cancer stem cells
have been demonstrated in different tumours [18–20]. In this review we focus on inflamma-
tion and its role in CRC stemness development through epithelial–mesenchymal transition
(EMT) as shown in Figure 2.




Figure 2. The intricate links between stemness, epithelial-mesenchymal transition and inflammation in cancer.  
2. Stem Cells and Their Markers in Colorectal Carcinoma 
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stem cells. Stem cells are self-renewing cells that maintain a capacity to proliferate, gener-
ating new stem cells and daughter cells that undergo differentiation and replenish the 
pool of functional cells. Stem cells are pluripotent—they can give rise to different lineages 
of daughter cells. Similarly, the traditional theory of cancer stem cells defines CSCs as a 
minor fraction of self-renewing malignant cells that maintain a low but steady level of 
unlimited proliferation. Unlimited proliferation maintains the tumour, but rapid growth 
is dependent on the fast-dividing progeny of CSCs. The low mitotic activity of CSCs pro-
tects them from those treatment modalities that are directed against actively dividing 
cells. Thus, CSCs can survive treatment and give rise to recurrences [10]. As well as the 
ability for self-renewal and heterogeneous lineage differentiation, CSCs possess the ca-
pacity for clonal tumour initiation, as well as seeding and colonization of distant metasta-
ses [11]. 
Cancer stem cells are also designated tumour-initiating cells (TICs), referring to their 
capacity to initiate tumour growth and recapitulate the whole heterogeneity of neoplastic 
tissues, if TICs are transferred to experimental animals. However, TICs are not synony-
mous with the first malignant cell giving rise to the cancer in human patients. 
Although the tumour-initiating ability is important in experimental designs, im-
munohistochemically detectable stem cell markers have practical value, especially in 
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2. Stem Cells and Their Markers in Colorectal Carcinoma
The concept of cancer stem cells initially paralleled the hypothesis of normal tissue
stem cells. Stem cells are self-renewing cells that maintain a capacity to proliferate, generat-
ing new stem cells and daughter cells that undergo differentiation and replenish the pool
of functional cells. Stem cells are pluripotent—they can give rise to different lineages of
daughter cells. Similarly, the traditional theory of cancer stem cells defines CSCs as a minor
fraction of self-renewing malignant cells that maintain a low but steady level of unlimited
proliferation. Unlimited proliferation maintains the tumour, but rapid growth is dependent
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on the fast-dividing progeny of CSCs. The low mitotic activity of CSCs protects them from
those treatment modalities that are directed against actively dividing cells. Thus, CSCs can
survive treatment and give rise to recurrences [10]. As well as the ability for self-renewal
and heterogeneous lineage differentiation, CSCs possess the capacity for clonal tumour
initiation, as well as seeding and colonization of distant metastases [11].
Cancer stem cells are also designated tumour-initiating cells (TICs), referring to their
capacity to initiate tumour growth and recapitulate the whole heterogeneity of neoplastic
tissues, if TICs are transferred to experimental animals. However, TICs are not synonymous
with the first malignant cell giving rise to the cancer in human patients.
Although the tumour-initiating ability is important in experimental designs, immuno-
histochemically detectable stem cell markers have practical value, especially in studies of
the formalin-fixed, paraplast-embedded human tissues representing the bulk of surgical
pathology samples.
Regarding CRC cell surface antigens, CD133, CD144, CD24, CD44, CD166, CD29,
ALDH1, LGR5 and CXCR4 are considered to be CSC markers [21–23]. No single marker
can identify all CSCs. Data regarding various individual CSC markers are controversial;
therefore, some authors have suggested that co-expression of different markers should
be evaluated to detect the stemness [24]. However, currently, there is no general set of
markers for all CSCs. In addition, studies have shown controversial results regarding
tumour progression and the role of CSC markers [24,25].
CD133 is a transmembrane glycoprotein that is involved in cell membrane organiza-
tion. It has been demonstrated in different types of cancers, where it is closely associated
with the Wnt/β-catenin signalling pathway [26–28]. In experimental models of CRC,
CD133+CD44+ cells are able to initiate tumours in nude mice [29]. However, some immuno-
histochemical studies strongly contradict the value of CD133 as a stem cell marker [30,31].
Thus, Czeczko et al. recently reported on a negative (sic!) correlation between CD133 ex-
pression and death rate, confirmed by univariate analysis. Although the correlation did
not reach significance in the multivariate analysis, the trend was opposite to the expected
association between stemness and worse prognosis [30]. In addition, Ilie et al. concluded
that CD133 alone cannot be used to show CSCs. Several hypotheses can be suggested to
explain the difference between in vitro and animal experiments versus studies of human
tumours. First, immunohistochemistry is influenced by technological variations regarding:
(1) fixation (none versus formalin, pH, time of fixation and cold ischemia); (2) features
of the primary antibody (clonality (monoclonal versus polyclonal), clone, concentration,
incubation temperature and time); (3) mode (heat-induced versus enzymatic versus none)
and features (pH, microwave, temperature, timing) of antigen retrieval; (4) choice of visual-
isation system; (5) scoring, among others. An indirect hint of technological reasons in the
given case is the high proportion of CD133-positive cases observed by immunohistochem-
istry: 35.9% of all studied cancers and even 44.8% of right-sided carcinomas, as reported by
Czeczko et al. 2021 [30]. Further, the inherent complexity of tumour tissues can provide
the background for redundant regulatory links. The network of these links could outweigh
certain linear biological mechanisms evident in controlled in vitro experiments [32].
CD44 (Figure 3) is a transmembrane glycoprotein that normally participates in cell–cell
interactions, adhesion of the cytoskeleton to the extracellular matrix and cell migration. In
animal experiments, CD44-positive malignant cells show the classic features of TICs. As few
as 100 CD44+ cells are sufficient to initiate tumour formation in nude mice [33]. In cancers,
CD44 is associated with clonality, metastatic spreading ability, resistance to chemotherapy
and lower overall survival [24,33–35]. Regarding the resistance to treatment, patient-
derived organoid analysis has shown an association between the resistance of organoids
to 5-fluorouracil and high CD44 expression in carcinomas of the upper gastrointestinal
tract [36]. Considering the prognosis, human and animal-based studies have shown
CD44 upregulation in bladder cancer, where CD44 overexpression has been associated
with the prognostically adverse muscle-invasive basal subtype of bladder cancer [14,37].
Pathogenetically, in several tumour models, up-regulation of CD44 and/or its variants has
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been linked to inflammation, the relevant mediators and the changes induced by chronic
inflammation [22,38].




Figure 3. CD44 expression in a colorectal carcinoma. Immunoperoxidase, original magnification 
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Figure 3. CD44 expression in a colorectal carcinoma. Immunoperoxidase, original magnifica-
tion 100×.
CD144 is a vascular endothelial cadherin [39]. In ca cer studies, it has helped to
identify true CSCs. Thus, Yuan et al. found that in mice injected with CD133+CD144+
TU177 cells, the tumorigenesis rate was significantly (p < 0.05) higher than that in mice
injected with TU177 cells [40]. Interestingly, in colorectal cancer, CD144 is expressed in
endothelial cells generated by CSCs, but also in the tumour itself.
CD24 is a small ucin-like cell surface glycoprotein involved in intracellular sig-
nalling [41] and cell clustering [42]. It is overexpressed in malignant cells in comparison
with normal tissues. Higher levels of CD24 are associated with worse survival, indirectly
suggesting a possible association with stemness [41]. However, several research teams have
questioned this correlation [23]. Recently, it has been shown that CD24 overexpression is an
early event in colorectal carcinogenesis. Hence, it can represent an oncogene rather than a
stem cell marker, although association with stemness is not excluded by these findings [41].
Interestingly, in stem cell clusters, CD24 seems to be expressed in deeper cells located
within the cluster. Thus, CD24 may be the adherent molecule connecting the cells within
the clusters [42]. Various hypotheses can follow. As Kapeleris et al. suggested, the higher
CD24 expression in cell clusters might suggest that the spherical clusters possess more
stemness than single cells and therefore are more aggressive [42]. Alternatively, cellular
clusters could have evolutionary benefit upon impact of hydrodynamic stress [43] and in-
teraction with platelets and/or inflammatory cells, e.g., neutrophils and macrophages [44].
In this case, CD24 would be functionally important for metastatic spread and thus be
associated with worse outcomes even via non-stemness mechanisms.
CD166 is known as an activated leukocyte cell adhesion molecule, belonging to the
immunoglobulin superfamily [45]. It is involved in angiogenesis and in haematopoiesis [46].
In the early studies of colorectal carcinoma, membranous expression of CD166 showed a
significant correlation with shorter survival [45]. However, the findings of a more recent
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meta-analysis suggest that CD166 expression decreases the risk of vascular invasion (odds
ratio 0.75; p = 0.017), and is not associated with overall survival, with the possible exception
of stage II colorectal carcinoma [46]. Specific combinations of markers of stem cells and
proteins reflecting the activity of β-catenin/mTOR signalling pathways, e.g., CD44/CD166
(p = 0.017), CD166/β-catenin (p = 0.036), CD44/β-catenin (p = 0.001) and CD44/CD166/β-
catenin (p = 0.001), could be predictors of poor survival in stage II CRC and/or development
of liver metastasis [47]. Co-expression of CD29 and CD44 has been tested to enrich the
panel of CSC markers, since CD29 is involved in EMT through cross talk with cadherins
and CD44 has been reported as marker for CSCs [48].
Aldehyde dehydrogenase 1 (ALDH1) is an intracellular enzyme. As it is involved in
the oxidation of cellular aldehydes, ALDH1 activity might influence drug resistance via
detoxification processes. In CRC, its immunohistochemical expression has been associated
with younger age (p = 0.003), gross ulcerations (p = 0.01) and the presence of vascular
invasion (confirmed by p = 0.05) [49].
LGR5 (leucine-rich G-protein coupled receptor 5) is a transmembrane glycoprotein.
Upon binding the ligand, LGR5 downstream activates the Wnt/β-catenin molecular path-
way leading to increased cellular proliferation [50]. In colorectal cancer, LGR5 has been
found in stem cells [51]. Three-dimensional colorectal cancer organoid models, expressing
LGR5, showed increased resistance to 5-fluorouracil and irinotecan in comparison with
non-stem-cell lines of colorectal cancer [51]. Notably, increased LGR5 gene expression has
already been shown in villous adenomas with a high-grade dysplasia, as well as in an
invasive carcinoma, when compared to normal colon cells [52].
CXCR4 is involved in chemotaxis, stemness and drug resistance [53]. Together with
LGR5, CXCR4 is considered a marker of CSCs, suggesting that targeting cells containing
these markers could improve CRC therapy results [54].
3. CRC Stemness and Epithelial–Mesenchymal Transition
Most colorectal tumours originate from epithelium. During carcinogenesis, intercellu-
lar contacts are weakened due to loss of intercellular junction proteins, e.g., E-cadherin,
β-catenin and others. Malignant cells further acquire mesenchymal features and markers
that promote invasion and movement within connective tissues. This cellular plasticity,
known as epithelial–mesenchymal transition (EMT), is a key event in distant metastatic
spread [21,22,55].
In CRC, EMT properties such as cytoskeletal deformability and motility, as well as
co-expression of EMT markers, are evident in small cell clusters, known as tumour buds
(Figure 4), as reviewed by Grigore et al. [56]. Recently, Sato et al. analysed 32 CRC cases
displaying tumour budding. They showed that cancer buds expressed various amounts
of LGR5 and PD-L1 and suggested that patients having PD-L1-negative tumour buds
should receive different treatment, affecting the CSC marker LGR5 [57]. Thus, tumour
budding can be closely associated with stemness. This linkage is not limited to CRC but is
likely to reflect a general feature of carcinogenesis. For example, in head and neck cancers,
tumour buds have shown EMT properties and increased expression of CSC markers,
leading to poor survival rates [58,59]. Tumour budding has been associated with a worse
prognosis in various carcinomas [60], paralleling the classic association between stemness
and adverse survival.
EMT in a cancer is triggered by complex signalling pathways that include regulation
via EMT transcription factors and/or microRNAs (miRNAs) [61]. The relevant transcription
factors include Snail, Slug, Twist-related protein 1 (Twist1), Zinc finger E-box binding
homeobox 1 (ZEB1) and ZEB2 [62].
Snail family transcription factors are best known in association with EMT. Overexpres-
sion of Snail has been associated with down-regulation of E-cadherin, leading to enhanced
cell migration and invasion (p < 0.002 versus control), as well as significantly higher ex-
pression of the CSC markers CD133 and CD44 [63]. Nevertheless, other authors have
reported that Snail1 expression in colorectal cancer lacks an association with E-cadherin
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levels. This could indirectly indicate other ways for EMT induction [64]. Overexpression
of transcription factors Snail and Twist1 can also be induced by environmental changes,
e.g., hypoxia, where CRC cell lines show changes in the levels of EMT markers such as
fibronectin and E-cadherin [65].




Figure 4. Manifestations of epithelial–mesenchymal transformation in colorectal carcinoma (CRC). (A)—Loss of E-cad-
herin in CRC. Note the retained E-cadherin expression in a normal colonic crypt. Immunoperoxidase (IP), original mag-
nification (OM) 200×. (B)—High E-cadherin expression in CRC. IP, OM 100×. (C)—Non-budding CRC. Visualisation by 
haematoxylin and eosin (HE), OM 40×. (D)—CRC with florid budding. HE, OM 100×. 
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Figure 4. anifestations of epithelial–mesenchymal transformation in colorectal carcinoma (CRC). (A)—Loss of E-cadherin
in CRC. Note the retained E-cadherin expression in a normal colonic crypt. Immunoperoxidase (IP), original magnification
(OM) 200×. (B)—High E-cadherin expression in CRC. IP, OM 100×. (C)—Non-budding CRC. Visualisation by haematoxylin
and eosin (HE), OM 40×. (D)—CRC with florid budding. HE, OM 100×.
The APC/Wnt/β-catenin signalling pathway is widely described in association with
EMT and Snail activity [66]. The Wnt signalling pathway is tightly regulated in normal
colon stem cells and is one of the most common pathways that is dysregulated in colon
cancer, not only in familial cases of CRC but also in the majority of sporadic CRC cases [67].
This pathway participates in a cell cycle in the undifferentiated stem cells in the base of the
colonic crypts, allowing survival of both normal and cancer stem cells [68]. Truncation of
the APC protein results in enhanced Wnt signalling by β-catenin, which stimulates tran-
scription of Wnt-targeted genes and enhances activation of T-cell factor (TCF) targets, with
a subsequent increase in a cell growth, differentiatio , spread a d adhesion of colorectal
c lls [69,70]. Disruption in β-catenin functi n is idely recognize in association with
different types of cancer, as well as myofibroblast activ ti n in pulmonar fibrosis [71].
In a mouse model, the link betwee EMT and CSC has been dem nstrated via E-
cad erin. Tamura et al. showed that, compared to E-cadherin-negative colorectal CSCs,
E-cad rin-positive cancer stem ce ls have higher tumour growth potential in vivo, via
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higher expression of the pluripotency factor NANOG, which contributes to elevated levels
of cyclins D1 and B1 [72]. In turn, oncogene cyclin D1 is responsible for cell cycle regulation,
i.e., progression from the G1 phase of the cell cycle to the S phase [73].
Another mechanism involved in CRC progression is associated with a pro-inflammatory
cytokine, TNFα, which is produced by macrophages and CD4-positive T lymphocytes.
TNFα has a crucial role in EMT, as it upregulates NF-κB signalling pathways, which
leads to overexpression of transcription factors Snail, Slug and Twist, leading to down-
regulation of E-cadherin and up-regulation of N-cadherin [74,75]. In addition, it stimulates
cell self-renewal by cross action, together with TGF-β [76,77]. TGF-β, produced by acti-
vated lymphocytes, induces NF-kappaB activation and EMT, and enhances stemness by
CD44 expression in colorectal cancer [78].
Tumour buds are proposed as a morphological sign of EMT in CRC tissues. There is
a significant interaction effect for tumour budding between CD44 variant 6 and nuclear
β-catenin (p = 0.01 by immunohistochemical expression), suggesting that up-regulation
of these proteins could contribute to the formation of tumour buds [79]. Yamada et al., in
2017, showed that expression of EMT-related proteins in surrounding stromal cells was
significantly higher in areas of high-grade tumour budding than in low-grade areas [80],
suggesting that there could be even more complex mechanisms involved within EMT,
besides those already known.
The pathways of EMT induction and stemness in CRC differ by microsatellite in-
stability (MSI) status. Twist1 induced EMT and CD44 via AKT/GSK-3β/β-catenin and
AKT/NF-kappaB pathways in microsatellite-stable (MSS) cells, while only the β-catenin
pathway was activated in MSI colorectal cancer cells [81].
4. Inflammation and Its Role in EMT and Cancer Stemness
Within CRC pathogenesis, inflammation plays a significant role, especially in patients
with an underlying chronic inflammatory illness such as Crohn’s disease or ulcerative
colitis. The risk of CRC-induced death in patients with inflammatory bowel disease is
higher than in individuals diagnosed with CRC only, even when adjusting for tumour
stage (hazard ratio HR 1.42; 95% confidence interval (CI): 1.16–1.75) [82].
Tumour-related inflammation has been studied in different cancers, targeting also the
associations with cancer stemness, particularly in relation to the levels of CD44, known
as a cancer stem cell marker. Suwannakul et al. recently described the expression of
CD44 within Opisthorchis viverrini infection-related cholangiocarcinoma. Higher expression
of CD44v9 was found in Opisthorchis viverrini infection-related cancers than in cholangio-
carcinomas that were not associated with this parasite. There was no CD44v9 staining in
the bile duct cells of normal liver. Authors also observed significantly higher expression
of inflammation-related markers such as S100P and COX-2 in infection-related cholan-
giocarcinoma compared to that in non-infected cases and normal liver. These results
suggest that stem cell marker CD44v9 may be related to inflammation-associated cancer
development [38].
In animal models of breast cancer, CD44 deletion from the malignant cells resulted
in delayed carcinogenesis. This finding was accompanied by a decrease in numbers of
infiltrating CD206-positive macrophages, known to be associated with tumour-promoting
functions [83]. In ovaries, CD44+ epithelial ovarian CSCs benefit from the TLR2-MyD88-
NFκB pathway, leading to a pro-inflammatory microenvironment that supports stem-cell-
driven repair and self-renewal [84].
In a study by Max et al., the relation between tumour budding and inflammation was
evaluated in 381 cases of CRC. A combined analysis of tumour budding and inflammatory
cell reaction showed that patients with high-grade budding and marked inflammation
had a better outcome with respect to both progression-free (p < 0.001) and cancer-specific
survival (p < 0.001) than patients with high-grade budding and only mild inflammation. It
was further confirmed by multivariate analysis that in cancers with high-grade budding,
marked inflammation is associated with better progression-free (HR 0.59; 95% CI: 0.38–0.92;
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p = 0.021) and cancer-specific (HR 0.58; 95% CI: 0.36–0.93; p = 0.024) survival [85]. The
association between intense budding and adverse survival has been confirmed by other
studies targeting the complex interactions between budding and inflammation/cancer
microenvironment in CRC [86]. Stem cell markers, e.g., LGR5, have been shown to be
present in the tumour buds [87].
The tumour microenvironment in CRC consists of multiple stromal and immune cell
types, including cancer-associated fibroblasts, pericytes, monocytes, macrophages and a
subset of T cells [88]. The numbers of CD66b-positive neutrophils are increased in CRC
in comparison to adjacent mucosa, and a high density of intratumoural neutrophils is an
independent factor for poor prognosis of patients with CRC. High counts of intratumoural
neutrophils positively correlated with pT, pM and clinical stage, all with p < 0.05 [89].
Although their role in cancer development is still controversial, eosinophils are able
to induce cancer cell apoptosis, as shown in direct studies of the interaction between
human eosinophils and a colorectal carcinoma cell line. The involved mechanisms include
CD11a/CD18 complex, eosinophil cationic protein and eosinophil-derived neurotoxin
mechanisms, as well as TNF-α secretion and granzyme A [90]. However, the role of
eosinophils in cancer is ambiguous. Thus, for instance, in early studies of cervical cancer,
high numbers of eosinophils were found to be associated with worse survival. This finding
was explained by a less appropriate immune response, i.e., a disturbed equilibrium between
Th1- and Th2-mediated reactions [91,92]. Similarly, marked tissue eosinophilia correlated
with an adverse prognosis in Hodgkin’s lymphoma [91,92]. In CRC, increased counts of
peritumoural and intratumoural eosinophils are significantly associated with lower T, N
and G parameters and absence of vascular invasion, as well as improved progression-free
and cancer-specific survival [93]. Prizment et al. showed that high numbers of stromal
eosinophils in CRC were associated with lower tumour stage and better overall and cancer-
specific 5-year survival, reflected by hazard ratios for death of 0.61 (95% CI: 0.36–1.02;
p = 0.02) and 0.48 (95% CI: 0.24–0.93; p = 0.01), respectively [94].
Tumour-associated macrophages (TAMs) represent an important component of the
tumour microenvironment. In a cohort of 81 CRC cases, the relationships of TAMs with
EMT markers (E-cadherin and vimentin) were analysed. The TAM antigens CD68 and
CD163 were mainly expressed at the tumour invasive front and stroma, while no expression
or only weak expression was observed in tumour nests. High levels of CD163 in the invasive
front were associated with down-regulation of E-cadherin and up-regulation of vimentin,
indicating EMT. Univariate and multivariate analyses indicated that CD163 expression at
the invasive front was an independent prognostic factor associated with poor recurrence-
free survival (HR 2.414; 95% CI: 1.016–4.523; p = 0.045 by multivariate assessment) and
overall survival (multivariate HR = 3.234, 95% CI: 1.176–8.889, p = 0.023 by multivariate
analysis) [95]. Macrophages are able to produce a wide spectrum of biologically active
substances. In vivo and in vitro experiments show that TAMs secrete higher levels of
osteopontin when cultivated together with CRC cells. Osteopontin, through binding to its
receptor CD44, activates c-jun-NH(2)-kinase signalling and promotes the clonogenicity of
CRC cells [96].
There are few studies looking at a stemness and inflammation as a whole. In a study
by Xu et al., the correlations between CRC stem cell markers, EMT and immune cells were
analysed. Within the tumour centre, the expression of the stemness marker NANOG weakly,
but statistically significantly negatively, correlated with CD3- (r = −0.163, p = 0.005), CD4-
(r = −0.129, p = 0.017) and CD8-positive (r = −0.120, p = 0.029) T lymphocytes, and expres-
sion of LGR5 negatively correlated with CD3-positive T lymphocytes (r = −0.165, p = 0.005).
There was no correlation between CD68-expressing macrophages and CSC markers in the
tumour centre, but high levels of CD44v6 in the invasive front were associated with more
CD68-positive macrophages (r = 0.211, p < 0.001) [97].
Recently, in a study by Gonzalez et al., the relationships between intratumoural
lymphocytes, tumour budding and stromal desmoplastic reaction were described. In-
tratumoural lymphocytes were associated with low budding (p = 0.0247). A competing
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risk analysis disclosed statistically significant prognostic groups combining intratumoural
lymphocytes and budding (p < 0.0001). Cases with intratumoural lymphocytes and low
budding were associated with better recurrence-free survival compared to cases lacking
intratumoural lymphocytes and showing intermediate or high budding (HR 0.214; 95% CI:
0.109–0.421) [98].
In mice models, overexpression of CXCR4 was recently found to promote the EMT
and infiltration of myeloid-derived suppressor cells and macrophages in colonic tissue,
accelerating colitis-associated and APC mutation-driven colorectal tumorigenesis and
progression [99]. Other stem cell markers have been shown to be present in a higher
amount in CRC budding areas, e.g., a statistically significant relationship was found
between the CSC markers Notch1, CD44 and ALDH1 and tumour budding [100].
Oncogenic protein MUC1 is a transmembrane protein with extracellular N-terminal
and transmembrane C-terminal subunits. MUC1-C is involved in the Wnt/β-catenin
signalling pathway, where it stabilizes β-catenin [101]. MUC1-C induces pro-inflammatory
effector TAK1, transforming growth factor β-activated kinase 1. Further, MUC1-C is also
linked to activation of the NF-κB pathway, leading to the induction of transcriptional
repressor ZEB1, which promotes EMT [102,103]. Finally, MUC1-C activates expression
of stem cell marker LGR5 as well as other CSC markers such as BMI1, ALDH1, FOXA1,
LIN28B, OCT4, SOX2 and NANOG. These results collectively support the involvement of
MUC1-C in driving inflammation, CRC cell stemness and self-renewal capacity [104].
IL-6 is produced by cells of mesenchymal origin. In CRC, CD90+ stromal fibrob-
lasts/myofibroblasts produce IL-6, which in turn up-regulates expression of the CSC
markers ALDH1 and LGR5 via an IL-6-dependent mechanism. In addition, stromal cells,
via IL-6, divert the inflammatory response towards a Th17-driven process favouring tu-
mour growth [105]. However, cancer-associated fibroblasts possess both tumour-promoting
and tumour-restraining functions. Selective depletion of α-smooth muscle actin-positive
cancer-associated fibroblasts resulted in increased tumour invasiveness, lymph node metas-
tasis and reduced overall survival. The underlying mechanism includes lower produc-
tion of BMP4 and increased TGFβ1 secretion from stromal cells, which in turn leads to
up-regulation of LGR5 CSCs and the development of an immunosuppressive microenvi-
ronment with increased frequency of Foxp3+ regulatory T cells and suppression of CD8+
T cells. Thus, the inflammation and the stemness are regulated via an intricate, balanced
biological network of cells and mediators [106].
In studies of cell lines, variations in stemness have been demonstrated in response
to chronic inflammation or the removal of it. Chronic inflammation suppressed LGR5 ex-
pression, but it was restored after the removal of injurious stimuli. Thus, cancer cells
recover their stemness levels after removal of inflammatory stimuli. Chronic inflammation
promoted the invasiveness of cancer cells and induced EMT via ZEB, but the invasive-
ness also decreased to normal levels after the removal of inflammatory stimuli. However,
TP53-mutated cells had higher cancer stemness and invasiveness than TP53 wild-type cells
under chronic inflammation [107].
The role of inflammation has been studied from the therapeutic point of view. Non-
steroidal anti-inflammatory drugs suppress CD133- and CD44-expressing stem cells of col-
orectal carcinoma via COX-2 inhibition. This effect was evident in a cell culture as well as an
in vivo mouse xenograft model [108]. For instance, in breast cancer cell cultures, combined
doxorubicin and aspirin treatment significantly reduced the proportion of cancer stem cells
and the colony-forming ability. This treatment delayed the inhibition of interleukin-6 secre-
tion, which is mediated by both COX-dependent and COX-independent pathways [109].
Targeting of CD24 might affect several pathogenetic pathways, such as stemness, clus-
tering of circulating cancer cells/CSCS and cytokine environment pathways [110,111].
Interestingly, 470 nm light irradiation inhibited the invasiveness of CD133-positive human
colorectal cancer stem cells by suppressing the cyclooxygenase-2/prostaglandin E2 path-
way [112].
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5. Conclusions
Our review shows multiple links between stemness, inflammation and epithelial–
mesenchymal transformation in colorectal carcinoma. These interactions are regulated
via an intricate, balanced biological network of cells and mediators. The inherent com-
plexity of tumour tissues can provide a background for redundant regulatory links. The
network of these links could outweigh certain linear biological mechanisms evident in
controlled in vitro experiments. Nevertheless, associations between stemness, inflamma-
tion and epithelial–mesenchymal transformation must be recognised when elaborating
new treatment regimens, as relatively simple anti-inflammatory treatment can suppress
stem cells.
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